TY - JOUR
T1 - Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment through Hypothesis-Driven Systems Medicine Using CoVex
AU - Matschinske, Julian
AU - Salgado-Albarrán, Marisol
AU - Sadegh, Sepideh
AU - Bongiovanni, Dario
AU - Baumbach, Jan
AU - Blumenthal, David B.
N1 - Publisher Copyright:
© 2020, Mary Ann Liebert, Inc, publishers 2020.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has developed into a pandemic causing major disruptions and hundreds of thousands of deaths in wide parts of the world. As of July 3, 2020, neither vaccines nor approved drugs for effective treatment are available. In this article, we showcase how to individuate drug targets and potentially repurposable drugs in silico using CoVex a recently presented systems medicine platform for COVID-19 drug repurposing. Starting from initial hypotheses, CoVex leverages network algorithms to individuate host proteins involved in COVID-19 disease mechanisms, as well as existing drugs targeting these potential drug targets. Our analysis reveals GLA, PLAT, and GGCX as potential drug targets, and urokinase, argatroban, dabigatran etexilate, betrixaban, ximelagatran and anisindione as potentially repurposable drugs.
AB - Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has developed into a pandemic causing major disruptions and hundreds of thousands of deaths in wide parts of the world. As of July 3, 2020, neither vaccines nor approved drugs for effective treatment are available. In this article, we showcase how to individuate drug targets and potentially repurposable drugs in silico using CoVex a recently presented systems medicine platform for COVID-19 drug repurposing. Starting from initial hypotheses, CoVex leverages network algorithms to individuate host proteins involved in COVID-19 disease mechanisms, as well as existing drugs targeting these potential drug targets. Our analysis reveals GLA, PLAT, and GGCX as potential drug targets, and urokinase, argatroban, dabigatran etexilate, betrixaban, ximelagatran and anisindione as potentially repurposable drugs.
KW - SARS-CoV-2
KW - network-based drug repurposing
KW - systems medicine
UR - http://www.scopus.com/inward/record.url?scp=85097003951&partnerID=8YFLogxK
U2 - 10.1089/adt.2020.1010
DO - 10.1089/adt.2020.1010
M3 - Review article
C2 - 33164550
AN - SCOPUS:85097003951
SN - 1540-658X
VL - 18
SP - 348
EP - 355
JO - Assay and Drug Development Technologies
JF - Assay and Drug Development Technologies
IS - 8
ER -
